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After activation, T cells diff erentiate into distinct 
eff ector populations according to the particular 
cytokine environment that surrounds them. High 
levels of IFN-γ generate a Th1 population that 
contributes to protection against bacteria and 
viruses, whereas an environment of IL-4 leads 
to development of Th2 cells that are protective 
against helminths (1). Allergic asthma is gener-
ally held to occur as a consequence of a dysregu-
lated Th2 response to environmental allergens, 
as it is characterized by increased levels of the 
Th2 cytokines IL-4, -5, -9, and -13 (2–4). 
Manipulation of Th2 function has been pro-
posed as a novel strategy for treatment of asthma, 
and enhancing Th1 responses in allergic individ-
uals has been proposed as one method of such a 
strategy. In mice, transfer of Th1 cells has been 
shown to down-regulate pathology induced by 
transfer of Th2 cells alone, and this inhibition has 
been shown to be IFN-γ dependent (5).
T cell Ig and mucin domain–containing 
molecule-3 (Tim-3) was described as a trans-
membrane protein preferentially expressed on 
Th1 cells (6). In a Th1-mediated model of ex-
perimental allergic encephalomyelitis (EAE), in 
vivo neutralization of Tim-3 resulted in increased 
disease severity. Two further studies suggested 
that Tim-3 function was required for peripheral 
tolerance and acquisition of transplantation tol-
erance, respectively (7, 8). In addition, galectin-9 
has recently been identifi ed as the ligand for 
Tim-3, and it has been demonstrated that ad-
ministration of galectin-9 induced selective death 
of Th1 cells and inhibited the development of 
EAE (9). Collectively, these studies implied that 
signaling through Tim-3 may negatively regulate 
Th1 responses, and thus suppression of Tim-3 
may inhibit Th2 responses such as allergic disease 
through enhancement of a Th1 response.
Tim-3 belongs to a novel family of genes 
that map to a region of chromosome 11 termed 
T cell and airway phenotype regulator (Tapr), which 
confers reduced Th2 responsiveness and protects 
against airway hyperreactivity (AHR) (10). Ex-
periments with mice have shown that the Tapr 
locus might regulate Th cell diff erentiation 
during primary antigen-specifi c responses (10). 
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T cell immunoglobulin and mucin domain–containing molecule-3 (Tim-3) is a surface 
molecule that is preferentially expressed on activated Th1 cells in comparison to Th2 cells. 
Blockade of Tim-3 has been shown to enhance Th1-driven pathology in vivo, suggesting 
that blockade of Tim-3 may improve the development of Th2-associated responses such as 
allergy. To examine the effects of Tim-3 blockade on the Th2 response in vivo, we adminis-
tered anti–Tim-3 antibody during pulmonary infl ammation induced by transfer of ovalbumin 
(OVA)-reactive Th2 cells, and subsequent aerosol challenge with OVA. In this model, anti–
Tim-3 antibody treatment before each airway challenge signifi cantly reduced airway 
hyperreactivity, with a concomitant decrease in eosinophils and Th2 cells in the lung. We 
examined Th1 and Th2 cytokine levels in the lung after allergen challenge and found that 
pulmonary expression of the Th2 cytokine IL-5 was signifi cantly reduced, whereas IFN-𝛄 
levels were signifi cantly increased by anti–Tim-3 antibody treatment. Thus, blocking Tim-3 
function has a benefi cial effect during pulmonary infl ammation by skewing the Th2 re-
sponse toward that of a Th1 type, suggesting an important role for Tim-3 in the regulation 
of allergic disease.
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Currently, the Tim gene family has eight members, Tim-1–8, 
and genomic analysis has revealed that an equivalent Tim fam-
ily of genes exists in humans (11). Polymorphisms in human 
Tim-1 and -3 have been associated with atopy, suggesting that 
the Tim family may have functional roles in human allergic 
diseases (12). In mouse, Tim-1–3 are reciprocally expressed by 
Th2 and Th1 cells during T cell diff erentiation, but their roles 
in the development of allergy and atopy have not yet been in-
vestigated. Therefore, we have used a monoclonal antibody to 
Tim-3 to determine the eff ect of Tim-3 blockade on develop-
ment of allergen-induced airway pathology and AHR in mice.
RESULTS AND D I S C U S S I O N 
Administration of anti–Tim-3 antibody decreased airway 
infl ammation induced by transfer of Th2 cells
Tim-3 has previously been found to be expressed by Th1 cells 
in vitro (6–8). Although allergen-induced airway infl ammation 
is considered to be primarily a Th2-driven disease, Tim-3 ex-
pression on CD4 cells increased in both airway lumen and lung 
tissue after either allergen sensitization and challenge or transfer 
of allergen-reactive Th2-polarized cells (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20062093/DC1).
Because we detected increased Tim-3 expression in the 
lung during allergen-induced airway disease, we assessed the 
eff ect of anti–Tim-3 antibody treatment on infl ammation in-
duced by transferring OVA-reactive, Th2-polarized cells into 
naive mice, and challenging with OVA through the airways 
(Fig. S2 A, available at http://www.jem.org/cgi/content/
full/jem.20062093/DC1). AHR was measured as changes in 
Penh, lung resistance, and compliance. Transfer of Th2 cells 
resulted in signifi cantly increased AHR compared with mice 
that received PBS instead of cells (Fig. 1, A–C). Interestingly, 
this AHR response was signifi cantly decreased by treatment 
with anti–Tim-3 antibody (Fig. 1, A–C).
We also assessed the eff ect of anti–Tim-3 antibody on 
lung tissue eosinophilia. Administration of anti–Tim-3 sig-
nifi cantly decreased eosinophil numbers in the lung tissue 
compared with mice that received control Ig (Fig. 2 A).
Because AHR and lung eosinophilia were reduced after 
anti–Tim-3 antibody treatment, we determined the magnitude 
of the lung Th2 response in the presence and absence of anti–
Tim-3 by examining numbers of Th2 cells in the lung tissue. 
Anti–Tim-3 treatment signifi cantly reduced Th2 cell numbers 
compared with mice that received control Ig (Fig. 2 B), sug-
gesting that blockade of Tim-3 can suppress the Th2 response.
In addition, we quantifi ed Th2 cytokine expression in 
bronchoalveolar lavage (BAL) supernatant after allergen 
challenge. Treatment of mice with anti–Tim-3 antibody sig-
nifi cantly reduced lung expression of IL-5; however, levels 
of the Th1-associated cytokine IFN-γ were signifi cantly in-
creased (Fig. 2, C and D). We also measured cytokine levels 
in lung tissue homogenate, and found that administration of 
anti–Tim-3 reduced IL-5 and -13 levels (which were unde-
tectable in BAL <0.5 pg/ml), although there was no substan-
tial eff ect on IFN-γ (Fig. S3, A–C, available at http://www
.jem.org/cgi/content/full/jem.20062093/DC1).
Anti–Tim-3 antibody decreases expression 
of proinfl ammatory chemokines after transfer 
of OVA-reactive Th2 cells
To determine whether the reduction in lung eosinophils 
and Th2 cells after anti–Tim-3 antibody treatment was caused 
by decreased recruitment of these leukocytes, lung levels of 
proinfl ammatory chemokines were determined. Administra-
tion of anti–Tim-3 antibody signifi cantly decreased levels 
of CCL11/eotaxin, CCL22/MDC, CCL17/TARC, CCL2/
MCP-1, CCL3/MIP-1α, and CCL5/RANTES compared 
with mice that received control Ig (Fig. 3). However, anti–
Tim-3 treatment had no eff ect on levels of CCL17/TARC 
or CCL3/MIP-1α (Fig. 3). It is interesting that anti–Tim-3 
treatment should reduce levels of CCL22/MDC, but not 
CCL17/TARC, as these chemokines both act on CCR4, 
which is postulated to play an important role in Th2 cell re-
cruitment (13). This suggests that CCL22/MDC may be the 
more dominant of these two chemokines in this model.
Monney et al. found that anti–Tim-3 treatment wors-
ened the Th1-mediated disease EAE by increasing macro-
phage activation, suggesting that Tim-3 signaling may be 
able to modulate macrophage function (6). Macrophages are 
Figure 1. Administration of anti–Tim-3 antibody inhibits the de-
velopment of AHR induced by transfer of polarized, OVA-reactive 
Th2 cells. AHR was measured 24 h after the fi nal OVA challenge by 
changes in Penh (A). Penh results were confi rmed by invasive measure-
ments of resistance (B) and compliance (C) in anesthetized and tracheos-
tomized mice. Results are expressed as the mean ± the SEM. n = 7–20 
mice/group from 2–4 independent experiments. *, P < 0.05, in comparison 
to Ig-treated mice.
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a source of many proinfl ammatory chemokines in the lung 
during allergic airway infl ammation; thus, altering macrophage 
function could potentially aff ect recruitment of Th2 cells and 
eosinophils to the lung. However, although Monney et al. 
found that macrophage function was increased by anti–
Tim-3 antibody, we found that the number of macrophages 
in the airway lumen and lung tissue are not changed by anti–
Tim-3 antibody (Fig. S4, available at http://www.jem.org/
cgi/content/full/jem.20062093/DC1), and that chemokine 
production in the lung is down-regulated by anti–Tim-3 
(Fig. 3), pointing toward a decrease in macrophage function. 
This could be caused by diff erences in the cytokine environ-
ment in allergen-induced airway infl ammation compared 
with EAE, or it could be that the suppression of lung infl am-
mation by anti–Tim-3 antibody treatment is not caused by a 
macrophage-mediated eff ect. Indeed, a more recent study has 
suggested that the ligand for Tim-3, galectin-9, is expressed 
predominantly on CD4+ T cells, and only on a small subset 
of CD11b+ cells (7, 9, 11), suggesting that the macrophage 
activation by anti–Tim-3 antibody treatment may have been 
a secondary consequence in the EAE model.
Administration of anti–Tim-3 antibody skews the Th2 
response to allergen toward a Th1 phenotype
Because blockade of Tim-3 has previously been found to 
augment Th1 responses (6, 7, 11), and given the increased 
expression of IFN-γ in the BAL, we sought to further estab-
lish the eff ect of anti–Tim-3 antibody treatment on cytokine 
expression in the lung. To this end, we performed intracel-
lular staining for IFN-γ and IL-5. The overall number of 
IL-5–producing cells in the lung was signifi cantly decreased 
by anti–Tim-3 antibody treatment, whereas the number of 
IFN-γ–producing cells were signifi cantly increased (Fig. 4, 
A and B). This refl ects the decreased levels of IL-5 in the BAL 
and lung, as measured by ELISA. However, we found that 
although IFNγ levels were decreased in BAL, there was no 
change in the lung IFN-γ levels, as measured by ELISA 
(Fig. 2 D and Fig. S3 C). It is conceivable that the down-
regulation of infl ammation and AHR is caused by the in-
creased BAL IFNγ levels in conjunction with increases in 
IFNγ-producing cells within local microenvironments in the 
lung. Cytokine production by individual cells within these 
tightly packed cellular microenvironments would induce 
changes in immunopathology, even though absolute values 
in the whole tissue, as measured by ELISA, are unchanged.
When cytokine-producing cells were defi ned by pheno-
type, the percentage of CD4 cells expressing IL-5 was signifi -
cantly decreased in the lungs of mice that were treated with 
anti–Tim-3 antibody compared with Ig controls (Fig. 4 C). 
In contrast, anti–Tim-3 treatment signifi cantly increased 
IFN-γ production from CD4 cells (Fig. 4 D). This increase 
in IFN-γ–producing CD4 cells could result from an induc-
tion in IFN-γ production from the host CD4 population or 
a switch to IFNγ production by the donor CD4 cells. To test 
this, we labeled the donor CD4 cells before transfer to the 
naive host mice. Although transferred CD4 cells produced 
IL-5, and this was unaff ected by Tim-3 blockade, IFN-γ ex-
pression was not detected in donor cells either before or after 
in vivo treatment with anti–Tim-3 antibody (Fig. 4 E and 
not depicted). However, in contrast, there was an increase in 
host-derived CD4 cells producing IFN-γ after Tim-3 anti-
body treatment. These data suggest that Tim-3 blockade 
aff ects the Th2 response in the lung, resulting in a more pro-
nounced Th1 phenotype in the bystander CD4 population 
rather than in the allergen-specifi c CD4 cells.
It has previously been shown that blockage of Tim-3 
signaling induces Th1 cell hyperproliferation and cytokine 
release in vitro and worsens Th1-mediated diseases in vivo 
Figure 2. Administration of anti–Tim-3 antibody decreases 
 eosinophil and Th2 cell numbers in the lung tissue after transfer 
of polarized OVA-reactive Th2 cells. Lung tissue cells were isolated as 
described in Materials and methods. Eosinophil numbers (A) were deter-
mined by differential counting of Wright-Giemsa–stained cytospins. Th2 
cell numbers (B) were determined by staining lung tissue digest cells with 
CD4 and the Th2 cell–specifi c marker T1/ST2. Pulmonary expression 
of IL-5 (C) and IFN-γ (D) was determined in BAL supernatant by ELISA. 
Data is expressed as the mean ± the SEM. n = 7–8 mice/group from 
2 independent experiments. *, P < 0.05, in comparison to Ig-treated mice.
Figure 3. Effect of administration of anti–Tim-3 antibody on 
proinfl ammatory chemokine production. Lung tissue levels of CCL5/
RANTES, CCL22/MDC, CCL17/TARC, CCL11/eotaxin, CCL2/MCP-1, and 
CCL3/MIP-1α were measured in lung tissue homogenate supernatant by 
ELISA in samples from mice treated with anti–Tim-3 antibody or Ig con-
trol. Data is expressed as the mean ± the SEM. n = 7–8 mice/group from 
2 independent experiments. *, P < 0.05, in comparison to Ig-treated mice.
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(7, 6, 11, 14). Although allergen-induced airway disease is 
considered to be a Th2-driven disease, it has also been shown 
that Th1 cells are recruited to the lung along with Th2 cells 
(15); indeed, we found an increase in Tim-3 expression in 
the lung after either allergen sensitization or adoptive trans-
fer of Th2 cells (Fig. S1). As Th1 and Th2 cells can cross-
regulate each other, anti–Tim-3 treatment may suppress 
Th2-mediated, allergen-induced infl ammation by inducing 
hyperproliferation of Th1 cells in the lung and increased 
IFN-γ expression. In support of this, previous studies have 
shown that cotransfer of Th1 cells or IL-12 treatment can at-
tenuate the airway infl ammation induced by transfer of Th2 
cells (5, 16, 17). Moreover, this attenuation was dependent 
on IFN-γ, rather than on direct suppression by Th1 cells, 
because airway infl ammation could not be inhibited in 
IFN-γR–defi cient mice or in the presence of an antibody 
against IFN-γ (5, 16). Indeed, a benefi cial role of IFN-γ in 
allergen-induced airway infl ammation has been demonstrated 
by several studies (18, 19). In support of this, we found sig-
nifi cant decreases in the Th2 cytokines IL-5 and -13, and an 
increase in BAL expression of the Th1 cytokine IFN-γ after 
anti–Tim-3 antibody treatment. Moreover, anti–Tim-3 anti-
body increased the number of host-derived CD4+ T cells se-
creting IFNγ, implying that anti–Tim-3 treatment infl uences 
the host bystander T cells, rather than skewing the donor Th2 
cells to a Th1 phenotype. Interestingly, it has previously been 
shown that blocking Tim-2, which is predominantly expressed 
on Th2 cells, has a benefi cial eff ect on the Th1-mediated dis-
ease EAE (20). We show that blocking Tim-3 suppresses 
Th2-driven allergic infl ammation, fi rmly implicating the Tim 
family in control of in vivo Th cell responses.
Anti–Tim-3 antibody treatment has no effect on expression 
of IL-10, TGF-𝛃, or FoxP3 in the lung
Sanchez-Fueyo et al. demonstrated a role for Tim-3 signal-
ing in the suppression of autoimmune disease mediated by 
CD4+CD25+ regulatory T cells (8). Previous studies have 
implicated IL-10 and TGF-β as important mediators in the 
regulation of immune responses by these cells (21–23). 
Therefore, we determined the levels of IL-10 and TGF-β in 
the lung after allergen challenge. We found no change in 
IL-10 (159 ± 19 pg/ml vs. 125 ± 10 pg/ml) or TGF-β (126 ± 
15 pg/ml vs. 152 ± 23 pg/ml) expression in the presence or 
absence of anti–Tim-3 antibody after allergen challenge. We 
also determined expression of the regulatory T cell marker 
FoxP3 in the lung and found that the percentage of CD4+ 
cells expressing FoxP3 was unchanged by anti–Tim-3 anti-
body treatment (5.5 ± 0.43% vs. 6.1 ± 0.51%).
Our data suggests that Tim-3 may not be involved in 
the suppressive function of CD4+CD25+ regulatory T cells 
in this setting. We have previously shown that CD4+CD25+ 
T cells can reduce allergen-induced airway infl ammation 
via induction of IL-10 in the lung (22). However, we found 
no diff erence in lung IL-10 expression, suggesting that 
CD4+CD25+ regulatory T cell function may not be aff ected. 
In addition, although we cannot discount IL-10 or TGF-β–
independent mechanisms of regulation, it could be argued 
that if signaling through Tim-3 were needed for regulation of 
infl ammation by CD4+CD25+ cells in this model, adminis-
tration of anti–Tim-3 would worsen allergen-induced airway 
infl ammation, rather than suppress it.
Administration of anti–Tim-3 antibody inhibited 
the development of allergen-induced airway infl ammation
We also used an allergen challenge model of airway infl am-
mation (Fig. S2 B) to determine the eff ect of blockade of 
Tim-3 on diff erent aspects of allergen-induced lung patho-
physiology. Although treatment with anti–Tim-3 had no 
signifi cant eff ect on AHR, both lung tissue eosinophils and 
Th2 cells were signifi cantly decreased in comparison with Ig 
control mice (Fig. 5, A–C). Despite this decrease in Th2 cells, 
lung expression of the Th2 cytokines IL-5 and -13 were only 
modestly decreased (Fig. 5 D), and there was no eff ect on 
IFN-γ (172 ± 35.7 pg/ml vs. 133 ± 16.6 pg/ml). These data 
indicate that a Tim-3 blockade can aff ect Th2 responses, 
even after active immunization with allergen. However, the 
Figure 4. Administration of anti–Tim-3 antibody reduces Th2 and 
enhances Th1 cytokine production in the lung. Percentages of IL-5+ (A), 
IFN-γ+ (B), CD4+IL-5+ (C), and CD4+IFN-γ+ (D) cells were determined 
in lung tissue digest by fl ow cytometric analysis. Data are expressed as 
the mean percentage of cells ± the SEM. n = 8–12 mice/group from 
2 independent experiments. *, P < 0.05, in comparison to Ig-treated mice. 
(E) Percentage contribution to IL-5 and IFN-γ production was assessed in 
host and transferred CD4 cells (by fl uorescent labeling of cells before 
injection) in lung tissue digest by fl ow cytometry. Data are expressed as 
the mean percentage of total cells producing IFN-γ ± the SEM. n = 6 
mice/group. *, P < 0.05, in comparison to Ig-treated mice.
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observation that Tim-3 blockade is more eff ective in sup-
pression of infl ammation induced by transfer of Th2 cells 
compared with that induced by allergen sensitization suggests 
that, in the latter model, other factors may also contribute to 
the development of the allergic response.
Modulation of Tim-3 function may be of therapeutic 
benefi t in Th2-mediated diseases
This is the fi rst report of a role for Tim-3 in a model of Th2-
mediated immunity. We observed a decrease in allergen-induced 
airway disease by anti–Tim-3 antibody treatment, accompanied 
by a shift toward Th1-mediated immunity. We postulate that 
because blockade of Tim-3 has previously been demonstrated 
to worsen Th1-mediated diseases through an enhanced Th1 
response, blockade of Tim-3 in a Th2-mediated disease such as 
allergic infl ammation is benefi cial because of cross-regulation of 
the Th2 response by Th1 cells. These data suggest that manipula-
tion of Tim-3 function may represent a novel therapy for asth-
matic patients.
MATERIALS AND METHODS
Animals
Female BALB/c mice (Harlan) were housed at Imperial College, London and 
used at 6–8 wk of age. UK Home Offi  ce guidelines for animal welfare based 
on the Animals (Scientifi c Procedures) Act of 1986 were strictly observed.
Induction of airway infl ammation by transfer of OVA-reactive, 
Th2-polarized cells
Airway infl ammation was generated by transfer of OVA-specifi c, Th2-
polarized cells in a modifi ed version of a previously published method (24). 
OVA-reactive CD4+ T cells were derived from spleens of BALB/c mice that 
had been sensitized 7 d before by i.p. injection of 0.1 mg OVA in alum 
(SERVA Electrophoresis). Splenocytes were resuspended in RPMI with 10% 
FCS, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, and 4 × 10−5% 
2-mercaptoethanol (all Sigma-Aldrich), and cultured for 5 d in the presence 
of 100 μg/ml OVA, 10 ng/ml recombinant IL-4 (Roche), and 10 μg/ml 
anti–IL-12 (C17.8). Th2-polarized CD4 T cells were purifi ed using a CD4 
isolation kit (Miltenyi Biotech). In some experiments, Th2-polarized cells 
were labeled using a cell-labeling kit according to the manufacturer’s proto-
col (Vybrant; Invitrogen). Purifi ed Th2-polarized cells were transferred into 
naive BALB/c mice at 106 cells per mouse i.v. Control mice received an 
equal volume of PBS i.v. All mice were challenged with 5% OVA (aerosol-
ized for 20 min) between days 1 and 7. 30 min before OVA challenge, mice 
were treated with 20 μg anti–Tim-3 antibody (8H7; a gift from Millen-
nium Pharmaceuticals, Inc., Cambridge, MA) i.p. or with control rat Ig 
(Stratech Scientifi c), killed 24 h after the fi nal OVA challenge, and analyzed 
(Fig. S2 A).
Induction of airway infl ammation by OVA sensitization 
and challenge
Airway infl ammation was generated as previously described (25). 30 min be-
fore OVA challenge, mice were treated with 20 μg anti–Tim-3 antibody 
i.p., killed 24 h after the fi nal OVA challenge, and analyzed (Fig. S2 B).
AHR
AHR was measured in mice 24 h after the fi nal OVA challenge by Penh, 
resistance, and compliance, as previously described (22).
Cell recovery
Airway lumen. BAL was performed, and diff erential leukocyte counts 
were performed as previously described (22).
Lung parenchyma. Lung tissue digests were prepared as previously described 
(22). Cytocentrifuge preparations were stained and counted as for BAL.
Flow cytometric analysis. BAL and lung tissue digest cells were stained 
and analyzed, as previously described (22). Antibodies used were anti-CD4, 
-CD8, -IL-5, -IFN-γ (BD Biosciences), -CD68 (Serotec), and -T1/ST2 
(Morwell Diagnostics). Tim-3 expression studies were performed by label-
ing anti–Tim-3 with a fl uorescent protein labeling kit according to the man-
ufacturer’s protocol (Invitrogen).
ELISAs
Cytokines were analyzed in BAL supernatant and lung tissue homogenate 
supernatants. Paired antibodies for IFN-γ, TGF-β (BD Biosciences), IL-5 
(Endogen), CCL11, CCL17, CCL22, CCL5, and CCL3 (R&D Systems) 
were used in sandwich ELISAs according to the manufacturer’s protocol. 
IL-13 (R&D Systems), IL-10 (eBiosciences), and CCL2 (BD Biosciences) 
ELISA kits were used according to the manufacturer’s protocol.
Data analysis
Graph generation and statistical analysis was performed by using Prism v4.00 
software (GraphPad).
Online supplemental material
Fig. S1 shows Tim-3 expression in lung after allergen challenge and transfer 
of Th2 cells. Fig. S2 shows the protocol used to induce allergic airway in-
fl ammation. Fig. S3 shows that anti–Tim-3 antibody treatment reduces Th2 
cytokine levels in lung tissue. Fig. S4 shows macrophage numbers in BAL 
and lung tissue. The online version of this article is available at http://www
.jem.org/cgi/content/full/jem.20062093/DC1.
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Figure 5. Administration of anti–Tim-3 antibody also reduces 
eosinophilia and Th2 cell numbers in an allergen sensitization and 
challenge model. Infl ammation was induced by sensitization and chal-
lenge (Fig. S2 B). AHR was measured 24 h after the fi nal OVA challenge by 
changes in Penh (A). Eosinophil (B) and Th2 cell numbers (C) were deter-
mined in lung tissue, as described in Materials and methods. Pulmonary 
expression of IL-5 and -13 (D) was determined in BAL supernatant by 
ELISA. Data is expressed as the mean ± the SEM. n = 7–8 mice/group. 
*, P < 0.05, in comparison to Ig-treated mice. Fig. S2 is available at 
http://www.jem.org/cgi/content/full/jem.20062093/DC1.
1294 TIM-3 BLOCKADE IN ALLERGEN-INDUCED AIRWAY INFLAMMATION | Kearley et al. 
Submitted: 29 September 2006
Accepted: 24 April 2007
REFERENCES
 1. Mosmann, T.R., and R.L. Coff man. 1989. Th1 and Th2 cells: diff erent 
patterns of lymphokine secretion lead to diff erent functional properties. 
Annu. Rev. Immunol. 7:145–173.
 2. Robinson, D.S., Q. Hamid, S. Ying, A. Tsicopoulos, J. Barkans, A.M. 
Bentley, C. Corrigan, S.R. Durham, and A.B. Kay. 1992. Predominant 
TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. 
N. Engl. J. Med. 326:298–304.
 3. Shimbara, A., P. Christodoulopoulos, A. Soussi-Gounni, R. Olivenstein, 
Y. Nakamura, R.C. Levitt, N.C. Nicolaides, K.J. Holroyd, A. Tsicopoulos, 
J.J. Lafi tte, et al. 2000. IL-9 and its receptor in allergic and nonallergic 
lung disease: increased expression in asthma. J. Allergy Clin. Immunol. 
105:108–115.
 4. Kroegel, C., P. Julius, H. Matthys, J.C. Virchow, and W. Luttmann. 
1996. Endobronchial secretion of interleukin-13 following local aller-
gen challenge in atopic asthma: relationship to interleukin-4 and eosino-
phil counts. Eur. Respir. J. 9:899–904.
 5. Cohn, L., R.J. Homer, N. Niu, and K. Bottomly. 1999. T helper 1 
cells and interferon γ regulate allergic airway infl ammation and mucus 
production. J. Exp. Med. 190:1309–1318.
 6. Monney, L., C.A. Sabatos, J.L. Gaglia, A. Ryu, H. Waldner, T. 
Chernova, S. Manning, E.A. Greenfi eld, A.J. Coyle, R.A. Sobel, et al. 
2002. Th1-specifi c cell surface protein Tim-3 regulates macrophage 
 activation and severity of an autoimmune disease. Nature. 415:536–541.
 7. Sabatos, C.A., S. Chakravarti, E. Cha, A. Schubart, A. Sanchez-Fueyo, X.X. 
Zheng, A.J. Coyle, T.B. Strom, G.J. Freeman, and V.K. Kuchroo. 2003. 
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses 
and induction of peripheral tolerance. Nat. Immunol. 4:1102–1110.
 8. Sanchez-Fueyo, A., J. Tian, D. Picarella, C. Domenig, X.X. Zheng, C.A. 
Sabatos, N. Manlongat, O. Bender, T. Kamradt, V.K. Kuchroo, et al. 2003. 
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses 
and promotes immunological tolerance. Nat. Immunol. 4:1093–1101.
 9. Zhu, C., A.C. Anderson, A. Schubart, H. Xiong, J. Imitola, S.J. Khoury, 
X.X. Zheng, T.B. Strom, and V.K. Kuchroo. 2005. The Tim-3 ligand 
galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 
6:1245–1252.
10. McIntire, J.J., S.E. Umetsu, O. Akbari, M. Potter, V.K. Kuchroo, 
G.S. Barsh, G.J. Freeman, D.T. Umetsu, and R.H. DeKruyff . 2001. 
Identifi cation of Tapr (an airway hyperreactivity regulatory locus) and 
the linked Tim gene family. Nat. Immunol. 2:1109–1116.
11. Meyers, J.H., C.A. Sabatos, S. Chakravarti, and V.K. Kuchroo. 2005. 
The TIM gene family regulates autoimmune and allergic diseases. Trends 
Mol. Med. 11:362–369.
12. Graves, P.E., V. Siroux, S. Guerra, W.T. Klimecki, and F.D. Martinez. 
2005. Association of atopy and eczema with polymorphisms in T-cell 
 immunoglobulin domain and mucin domain–IL-2-inducible T-cell kinase 
gene cluster in chromosome 5q33. J. Allergy Clin. Immunol. 116:650–656.
13. Bonecchi, R., G. Bianchi, P.P. Bordignon, D. D’Ambrosio, R. Lang, 
A. Borsatti, S. Sozzani, P. Allavena, P.A. Gray, A. Mantovani, and F. 
Sinigaglia. 1998. Diff erential expression of chemokine receptors and 
chemotactic responsiveness of T helper type 1 cells (Th1s) and Th2s. 
J. Exp. Med. 187:129–134.
14. Koguchi, K., D.E. Anderson, L. Yang, K.C. O’Connor, V.K. Kuchroo, 
and D.A. Hafl er. 2006. Dysregulated T cell expression of TIM3 in mul-
tiple sclerosis. J. Exp. Med. 203:1413–1418.
15. Randolph, D.A., R. Stephens, C.J.L. Carruthers, and D.D. Chaplin. 
1999. Cooperation between Th1 and Th2 cells in a murine model of 
eosinophilic airway infl ammation. J. Clin. Invest. 104:1021–1029.
16. Huang, T.J., P.A. MacAry, P. Eynott, A. Moussavi, K.C. Daniel, P.W. 
Askenase, D.M. Kemeny, and K.F. Chung. 2001. Allergen-specifi c Th1 
cells counteract eff erent Th2 cell-dependent bronchial hyperresponsive-
ness and eosinophilic infl ammation partly via IFN-gamma. J. Immunol. 
166:207–217.
17. Gavett, S.H., D.J. O’Hearn, X. Li, S.K. Huang, F.D. Finkelman, and 
M. Wills-Karp. 1995. Interleukin 12 inhibits antigen-induced airway 
hyperresponsiveness, infl ammation, and Th2 cytokine expression in mice. 
J. Exp. Med. 182:1527–1536.
18. Yoshida, M., R. Leigh, K. Matsumoto, J. Wattie, R. Ellis, P.M. 
O’Byrne, and M.D. Inman. 2002. Eff ect of interferon-gamma on aller-
gic airway responses in interferon-gamma-defi cient mice. Am. J. Respir. 
Crit. Care Med. 166:451–456.
19. Lack, G., H. Renz, J. Saloga, K.L. Bradley, J. Loader, D.Y. Leung, G. Larsen, 
and E.W. Gelfand. 1994. Nebulized but not parenteral IFN-gamma de-
creases IgE production and normalizes airways function in a murine 
model of allergen sensitization. J. Immunol. 152:2546–2554.
20. Chakravarti, S., C.A. Sabatos, S. Xiao, Z. Illes, E.K. Cha, R.A. Sobel, X.X. 
Zheng, T.B. Strom, and V.K. Kuchroo. 2005. Tim-2 regulates T helper 
type 2 responses and autoimmunity. J. Exp. Med. 202:437–444.
21. Asseman, C., S. Mauze, M.W. Leach, R.L. Coff man, and F. Powrie. 1999. 
An essential role for interleukin 10 in the function of regulatory T cells 
that inhibit intestinal infl ammation. J. Exp. Med. 190:995–1004.
22. Kearley, J., J.E. Barker, D.S. Robinson, and C.M. Lloyd. 2005. 
Resolution of airway infl ammation and hyperreactivity after in vivo 
transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. 
J. Exp. Med. 202:1539–1547.
23. Powrie, F., J. Carlino, M.W. Leach, S. Mauze, and R.L. Coff man. 1996. 
A critical role for transforming growth factor-β but not interleukin 4 
in the suppression of T helper type 1–mediated colitis by CD45RBlow 
CD4+ T cells. J. Exp. Med. 183:2669–2674.
24. Mattes, J., M. Yang, A. Siqueira, K. Clark, J. MacKenzie, A.N.J. 
McKenzie, D.C. Webb, K.I. Matthaei, and P.S. Foster. 2001. IL-13 
induces airways hyperreactivity independently of the IL-4R alpha chain 
in the allergic lung. J. Immunol. 167:1683–1692.
25. McMillan, S.J., B. Bishop, M.J. Townsend, A.N. McKenzie, and C.M. 
Lloyd. 2002. The absence of interleukin 9 does not aff ect the develop-
ment of allergen-induced pulmonary infl ammation nor airway hyper-
reactivity. J. Exp. Med. 195:51–57.
